These emerging therapies , Semaglutide , represent a significant advancement in managing obesity and possibly related conditions . These drugs are grouped as GLP-1 hormone stimulators, meaning they function to mimic the endogenous GLP-1 hormone , enhancing glucose secretion and lowering hunger .